Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)-Reference-Cited by-同舟云学术

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Published:2008-05 Issue:9625 Volume:371 Page:1675-1684
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Papp Kim A,Langley Richard G,Lebwohl Mark,Krueger Gerald G,Szapary Philippe,Yeilding Newman,Guzzo Cynthia,Hsu Ming-Chun,Wang Yuhua,Li Shu,Dooley Lisa T,Reich Kristian

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Psoriasis pathophysiology: current concepts of pathogenesis;Krueger;Ann Rheum Dis,2005

2. Pathogenesis and therapy of psoriasis;Lowes;Nature,2007

3. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment;Koo;Dermatol Clin,1996

4. Psoriasis;Schon;N Engl J Med,2005

5. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis;Krueger;N Engl J Med,2007

Cited by 1279 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection;Cureus;2024-09-03

2. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis;Journal of the American Academy of Dermatology;2024-09

3. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

4. Long‐term use of lokivetmab in dogs with atopic dermatitis;Veterinary Dermatology;2024-08-14

5. Physiologically-based pharmacokinetic modeling to predict the exposure and provide dosage regimens of Ustekinumab in pediatric patients with inflammatory bowel disease;European Journal of Pharmaceutical Sciences;2024-08